A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients

Kozue Takeshita, Shinta Mizuno, Yohei Mikami, Tomohisa Sujino, Keiichiro Saigusa, Katsuyoshi Matsuoka, Makoto Naganuma, Tadashi Sato, Toshihiko Takada, Hirokazu Tsuji, Akira Kushiro, Koji Nomoto, Takanori Kanai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Imbalance of the intestinal microbiota is associated with gastrointestinal disease and autoimmune disease and metabolic syndrome. Analysis of the intestinal microbiota has recently progressed, and the association with inflammatory bowel disease has been reported at the species level. Such findings suggest that the recovery of homeostasis in the intestinal microbiota could cure inflammatory bowel disease. We aimed to search new probiotic candidates for inflammatory bowel disease through translational research by analysis of ulcerative colitis (UC) patients' intestinal microbiota and clarify the effects of them on inflammation. Here, we focused on Fusicatenibacter saccharivorans, which belongs to Clostridium subcluster XIVa and was successfully isolated and cultured in 2013. We analyzed the association of F. saccharivorans to UC patients' activity and inflammation for the first time. Methods: Feces from UC patients and healthy controls were analyzed by 16S ribosomal RNA gene sequences. F. saccharivorans was administered to murine colitis model. Colitic lamina propria mononuclear cells from UC patients and mice were stimulated with F. saccharivorans. Results: The whole fecal bacteria in active UC patients were less than that in quiescent UC patients. Furthermore, F. saccharivorans was decreased in active UC patients and increased in quiescent. The administration of F. saccharivorans improved murine colitis. F. saccharivorans induced interleukin 10 production by lamina propria mononuclear cells from not only colitis model mice but also UC patients. Conclusions: F. saccharivorans decreased in correlation to UC activity and suppresses intestinal inflammation. These results suggest that F. saccharivorans could lead to a novel UC treatment.

Original languageEnglish
Pages (from-to)2802-2810
Number of pages9
JournalInflammatory Bowel Diseases
Volume22
Issue number12
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Clostridium
Ulcerative Colitis
Colitis
Inflammatory Bowel Diseases
Inflammation
Mucous Membrane
16S Ribosomal RNA
Translational Medical Research
Gastrointestinal Diseases
Probiotics
rRNA Genes
Feces
Interleukin-10
Autoimmune Diseases
Homeostasis
Bacteria

Keywords

  • Clostridium subcluster XIVa
  • colitis
  • dysbiosis
  • Fusicatenibacter saccharivorans
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients. / Takeshita, Kozue; Mizuno, Shinta; Mikami, Yohei; Sujino, Tomohisa; Saigusa, Keiichiro; Matsuoka, Katsuyoshi; Naganuma, Makoto; Sato, Tadashi; Takada, Toshihiko; Tsuji, Hirokazu; Kushiro, Akira; Nomoto, Koji; Kanai, Takanori.

In: Inflammatory Bowel Diseases, Vol. 22, No. 12, 01.12.2016, p. 2802-2810.

Research output: Contribution to journalArticle

Takeshita, K, Mizuno, S, Mikami, Y, Sujino, T, Saigusa, K, Matsuoka, K, Naganuma, M, Sato, T, Takada, T, Tsuji, H, Kushiro, A, Nomoto, K & Kanai, T 2016, 'A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients', Inflammatory Bowel Diseases, vol. 22, no. 12, pp. 2802-2810. https://doi.org/10.1097/MIB.0000000000000972
Takeshita, Kozue ; Mizuno, Shinta ; Mikami, Yohei ; Sujino, Tomohisa ; Saigusa, Keiichiro ; Matsuoka, Katsuyoshi ; Naganuma, Makoto ; Sato, Tadashi ; Takada, Toshihiko ; Tsuji, Hirokazu ; Kushiro, Akira ; Nomoto, Koji ; Kanai, Takanori. / A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients. In: Inflammatory Bowel Diseases. 2016 ; Vol. 22, No. 12. pp. 2802-2810.
@article{a033a3d705fb42d78947a3448e897e9b,
title = "A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients",
abstract = "Background: Imbalance of the intestinal microbiota is associated with gastrointestinal disease and autoimmune disease and metabolic syndrome. Analysis of the intestinal microbiota has recently progressed, and the association with inflammatory bowel disease has been reported at the species level. Such findings suggest that the recovery of homeostasis in the intestinal microbiota could cure inflammatory bowel disease. We aimed to search new probiotic candidates for inflammatory bowel disease through translational research by analysis of ulcerative colitis (UC) patients' intestinal microbiota and clarify the effects of them on inflammation. Here, we focused on Fusicatenibacter saccharivorans, which belongs to Clostridium subcluster XIVa and was successfully isolated and cultured in 2013. We analyzed the association of F. saccharivorans to UC patients' activity and inflammation for the first time. Methods: Feces from UC patients and healthy controls were analyzed by 16S ribosomal RNA gene sequences. F. saccharivorans was administered to murine colitis model. Colitic lamina propria mononuclear cells from UC patients and mice were stimulated with F. saccharivorans. Results: The whole fecal bacteria in active UC patients were less than that in quiescent UC patients. Furthermore, F. saccharivorans was decreased in active UC patients and increased in quiescent. The administration of F. saccharivorans improved murine colitis. F. saccharivorans induced interleukin 10 production by lamina propria mononuclear cells from not only colitis model mice but also UC patients. Conclusions: F. saccharivorans decreased in correlation to UC activity and suppresses intestinal inflammation. These results suggest that F. saccharivorans could lead to a novel UC treatment.",
keywords = "Clostridium subcluster XIVa, colitis, dysbiosis, Fusicatenibacter saccharivorans, ulcerative colitis",
author = "Kozue Takeshita and Shinta Mizuno and Yohei Mikami and Tomohisa Sujino and Keiichiro Saigusa and Katsuyoshi Matsuoka and Makoto Naganuma and Tadashi Sato and Toshihiko Takada and Hirokazu Tsuji and Akira Kushiro and Koji Nomoto and Takanori Kanai",
year = "2016",
month = "12",
day = "1",
doi = "10.1097/MIB.0000000000000972",
language = "English",
volume = "22",
pages = "2802--2810",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A single species of clostridium Subcluster XIVa decreased in ulcerative colitis patients

AU - Takeshita, Kozue

AU - Mizuno, Shinta

AU - Mikami, Yohei

AU - Sujino, Tomohisa

AU - Saigusa, Keiichiro

AU - Matsuoka, Katsuyoshi

AU - Naganuma, Makoto

AU - Sato, Tadashi

AU - Takada, Toshihiko

AU - Tsuji, Hirokazu

AU - Kushiro, Akira

AU - Nomoto, Koji

AU - Kanai, Takanori

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Imbalance of the intestinal microbiota is associated with gastrointestinal disease and autoimmune disease and metabolic syndrome. Analysis of the intestinal microbiota has recently progressed, and the association with inflammatory bowel disease has been reported at the species level. Such findings suggest that the recovery of homeostasis in the intestinal microbiota could cure inflammatory bowel disease. We aimed to search new probiotic candidates for inflammatory bowel disease through translational research by analysis of ulcerative colitis (UC) patients' intestinal microbiota and clarify the effects of them on inflammation. Here, we focused on Fusicatenibacter saccharivorans, which belongs to Clostridium subcluster XIVa and was successfully isolated and cultured in 2013. We analyzed the association of F. saccharivorans to UC patients' activity and inflammation for the first time. Methods: Feces from UC patients and healthy controls were analyzed by 16S ribosomal RNA gene sequences. F. saccharivorans was administered to murine colitis model. Colitic lamina propria mononuclear cells from UC patients and mice were stimulated with F. saccharivorans. Results: The whole fecal bacteria in active UC patients were less than that in quiescent UC patients. Furthermore, F. saccharivorans was decreased in active UC patients and increased in quiescent. The administration of F. saccharivorans improved murine colitis. F. saccharivorans induced interleukin 10 production by lamina propria mononuclear cells from not only colitis model mice but also UC patients. Conclusions: F. saccharivorans decreased in correlation to UC activity and suppresses intestinal inflammation. These results suggest that F. saccharivorans could lead to a novel UC treatment.

AB - Background: Imbalance of the intestinal microbiota is associated with gastrointestinal disease and autoimmune disease and metabolic syndrome. Analysis of the intestinal microbiota has recently progressed, and the association with inflammatory bowel disease has been reported at the species level. Such findings suggest that the recovery of homeostasis in the intestinal microbiota could cure inflammatory bowel disease. We aimed to search new probiotic candidates for inflammatory bowel disease through translational research by analysis of ulcerative colitis (UC) patients' intestinal microbiota and clarify the effects of them on inflammation. Here, we focused on Fusicatenibacter saccharivorans, which belongs to Clostridium subcluster XIVa and was successfully isolated and cultured in 2013. We analyzed the association of F. saccharivorans to UC patients' activity and inflammation for the first time. Methods: Feces from UC patients and healthy controls were analyzed by 16S ribosomal RNA gene sequences. F. saccharivorans was administered to murine colitis model. Colitic lamina propria mononuclear cells from UC patients and mice were stimulated with F. saccharivorans. Results: The whole fecal bacteria in active UC patients were less than that in quiescent UC patients. Furthermore, F. saccharivorans was decreased in active UC patients and increased in quiescent. The administration of F. saccharivorans improved murine colitis. F. saccharivorans induced interleukin 10 production by lamina propria mononuclear cells from not only colitis model mice but also UC patients. Conclusions: F. saccharivorans decreased in correlation to UC activity and suppresses intestinal inflammation. These results suggest that F. saccharivorans could lead to a novel UC treatment.

KW - Clostridium subcluster XIVa

KW - colitis

KW - dysbiosis

KW - Fusicatenibacter saccharivorans

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84994614224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994614224&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000972

DO - 10.1097/MIB.0000000000000972

M3 - Article

C2 - 27824645

AN - SCOPUS:84994614224

VL - 22

SP - 2802

EP - 2810

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 12

ER -